Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 20Recurrence 5Leukemia, Myeloid, Acute 4Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Waldenstrom Macroglobulinemia 1Renal Insufficiency 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoglobulin Light-chain Amyloidosis 1Hypergammaglobulinemia 1Hodgkin Disease 1Hematologic Diseases 1Disease 1Breast Neoplasms 1

Interventions

obinutuzumab 1ioflupane 1idelalisib 1daratumumab 1alovudine 1Vindesine 1Vincristine 1Rituximab 1Prednisone 1Positron Emission Tomography Computed Tomography 1Mitomycin 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Ga(III)-DOTATOC 1Doxorubicin 1Dexamethasone 1Cyclophosphamide 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Disease × daratumumab × Clear all
NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Anaveon AG

Phase 1 Terminated
4 enrolled
Plasma cell

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡